<p>The clinical consequences of biofilm-related infections are on the rise. Biofilm-related infections represent a mounting burden on healthcare worldwide, posing a significant challenge to patient care and health infrastructure. Another notorious function that needs to be underlined is the association of biofilms with medical devices. Considering the fact that bacteria under biofilm make them virulent and resistant to antibiotics, targeting the biofilms is a crucial area of investigation. Therefore, alternative approaches that extend beyond conventional antibiotic therapies are necessary to overcome biofilm-related infections. In this regard, <i>Lactiplantibacillus plantarum</i>, a probiotic bacterium, has lately shown promising outcomes as an antibiofilm agent. Largely renowned for its antimicrobial metabolite production, <i>L. plantarum</i> could be a potential alternative to improve biofilm-related treatment and its cost associated with biofilm infections. Therefore, the present review aims to provide a comprehensive understanding and implications of <i>L. plantarum</i> as an antibiofilm agent regardless of its biological form against pathogens in healthcare. Additionally, the potential of <i>L. plantarum</i> as a biofilm producer and its engineered applications in clinical applications and therapeutic use will also be discussed in this review.</p>